Niort G, Gambino R, Cassader M, Pagano G
Istituto di Medicina Interna, University of Torino, Italy.
Horm Metab Res. 1993 Jul;25(7):372-4. doi: 10.1055/s-2007-1002122.
To assess bezafibrate efficacy in a diabetic population a single-blind randomized study was performed in 32 diet-resistant type IIb hyperlipidaemic non-insulin-dependent (NID) diabetic patients in good metabolic control (HbA1c < 8%) compared to a placebo group. In our diabetic patients one month treatment of 400 mg/day bezafibrate lowered plasma C (-14%) and TG (-37%) and globally reduced the VLDL particles and VLDL lipids (-37% for C, -56% for TG and -25% for PL), raising VLDL C/TG ratio (+46%), redistributing TG from VLDL to LDL (+10%) and mainly in HDL (+49%), lowered LDL-C and Apo B levels and increased HDL-C together with Apo A1 (+19% and +13%) and Apo A1/Apo B (+72%). PL were raised by bezafibrate treatment and were redistributed from VLDL (-25%) to LDL (+25%) and HDL (+18%), while PL/C ratio increased in VLDL and in LDL (+18% and +50% respectively). Bezafibrate use was safe and improved the lipid pattern and the apolipoprotein and lipid distribution in the lipoproteins, producing a less atherogenic pattern in our NID diabetics.
为评估苯扎贝特在糖尿病患者中的疗效，我们进行了一项单盲随机研究，将32名代谢控制良好（糖化血红蛋白<8%）、饮食控制无效的IIb型高脂血症非胰岛素依赖型（NID）糖尿病患者与安慰剂组进行比较。在我们的糖尿病患者中，每天400毫克苯扎贝特治疗一个月可降低血浆胆固醇（-14%）和甘油三酯（-37%），总体上减少极低密度脂蛋白颗粒和极低密度脂蛋白脂质（胆固醇-37%，甘油三酯-56%，磷脂-25%），提高极低密度脂蛋白胆固醇/甘油三酯比值（+46%），将甘油三酯从极低密度脂蛋白重新分配到低密度脂蛋白（+10%），主要是重新分配到高密度脂蛋白（+49%），降低低密度脂蛋白胆固醇和载脂蛋白B水平，增加高密度脂蛋白胆固醇以及载脂蛋白A1（分别增加+19%和+13%）和载脂蛋白A1/载脂蛋白B（+72%）。苯扎贝特治疗可使磷脂升高，并从极低密度脂蛋白（-25%）重新分配到低密度脂蛋白（+25%）和高密度脂蛋白（+18%），而极低密度脂蛋白和低密度脂蛋白中的磷脂/胆固醇比值增加（分别增加+18%和+50%）。使用苯扎贝特是安全的，可改善脂蛋白的脂质模式、载脂蛋白和脂质分布，在我们的NID糖尿病患者中产生较少的动脉粥样硬化模式。
